CHAPTER 16 Allograft Osteochondral Transplantation
The treatment of chondral defects presents a formidable challenge. A variety of treatment methods are available, but all have shortcomings.1 Osteochondral allografts have been used for the treatment of chondral lesions for more than 20 years.2 They have the advantage of providing true articular cartilage rather than hyaline-like cartilage or fibrocartilage. They are particularly valuable when treating large defects and those with bone loss because they are not limited by size, depth, or shape of the lesion.
BASIC SCIENCE
Although the efficacy of osteochondral allografts has been shown for many years, disease transmission continues to be the area of greatest concern.3 Unfortunately, methods used to sterilize tissue have significant detrimental effects on osteochondral allografts.4 Sterilization methods not only devitalize all the chondrocytes, but also have negative effects on the material properties of the graft. Fortunately, the risk of disease transmission is slight if the tissue is retrieved, handled, and processed in strict accordance with standardized guidelines of the American Association of Tissue Banks (AATB).5
The initial clinical series reported using grafts within 1 week from procurement because it was found that the sooner the graft is implanted, the greater the chance of chondrocyte survival.6,7 Although the minimum chondrocyte viability for graft success is unknown, it is clear that this play a vital role in graft integrity.8 However, disease testing and safety precautions have resulted in tissue banks generally not releasing grafts for use until about 3 weeks. Fortunately, current storage methods are able to maintain 80% cell viability at 4 weeks.9,10 In addition, the biomechanical properties of the graft are not statistically affected at that time.11,12 However, more recent testing has shown that in commercially available grafts, a large percentage of the viable cells do not exhibit full function.13
Because of the limitations of fresh grafts with regard to storage and assurance of sterility, other methods of preservation, including freeze drying and fresh-frozen methods, have been evaluated.14 Unfortunately, fresh-frozen grafts have no viable chondrocytes. Freeze drying not only destroys all cells but also alters the graft’s material properties.15
Host immune response is another area of concern with allograft transplantation. It is well known that musculoskeletal allografts are capable of inducing cell-mediated and humeral immune responses in the host.16,17 The predominant mechanism is cell-mediated, and by reducing the number of allogenic cells, the immune response would therefore be reduced. The primary source of allograft cells is the blood and bone marrow elements. The immune load is significantly reduced by removing them during graft processing,.
Chondrocytes can also evoke an immune response and matching the surface antigens has been presented as one method to reduce the load further. However, the limited number of osteochondral allografts available would make it extremely difficult to match the donor to the recipient. Fortunately, any host sensitization has not precluded favorable results. It has been suggested that because chondrocytes are embedded in the dense matrix, which acts as a barrier, intact grafts are considered immunologically privileged. However, there is a consensus that patients with autoimmune disease or inflammatory arthropathies are not appropriate candidates for osteochondral allografts. Although it may be implemented, the morbidity associated with immunosuppression does not justify its use.
PATIENT EVALUATION
History and Physical Examination
Candidates for osteochondral allografts for focal defects typically fall into three categories—osteochondritis dissecans (OCD), post-traumatic lesions, and revision surgery.18–20
TREATMENT
Conservative Management
Focal chondral defects are a common finding and can have a significant effect on limiting a patient’s activities and quality of life.21,22 Symptomatic lesions can be treated nonoperatively with modification of activities, anti-inflammatories, viscosupplementation, and rehabilitation. Although these can be of benefit, many patients continue to be symptomatic.
Surgical Treatment
Several surgical options are available in addition to osteochondral allografts, but each has its advantages and disadvantages. The simplest is débridement-chondroplasty, but the benefits are commonly short-lived. Microfracture is technically easy to perform, with limited morbidity, but results in fibrocartilage filling the defect.23,24 As a result, the outcomes deteriorate after a few years, and lesions larger than a few centimeters do poorly. Autogenous osteochondral transfer has the benefit of improving normal articular cartilage and being able to fill bone deficiencies.25,26 However, donor availability is limited and it is recommended for lesions smaller than 2 to 2.5 cm2. Autologous chondrocyte implantation (ACI) is often discussed as an alternative to osteochondral allografts. It can also treat large lesions and is recommended for lesions up to 16 cm2.27 However, it results in hyaline-like cartilage and should not be used by itself for defects more than 6 to 8 mm deep. In addition, it is technically challenging, with many published studies having a reoperation rate of 30%.